Increases in cytokine and antimicrobial peptide gene expression in horses by immunomodulation with propionibacterium acnes

Veterinary Therapeutics

Volumn 4, Issue 1, 2003, Pages

  Davis, Elizabeth G ^a   Rush, Bonnie R ^a   Blecha, Frank ^a  

^a USDA National Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EQUIDAE; PROPIONIBACTERIUM ACNES;

EID: 79251496126     PISSN: 15283593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Rush BR, Flaminio MJ: Immunomodulation in horses. Vet Clin North Am Equine Pract 16(1):183-197, 2000.
2. Blecha F: Immunomodulators for prevention and treatment of infectious diseases in food-producing animals. Vet Clin North Am Food Anim Pract 17(3):621-633, 2001.
3. Evans DR, Rollins JB, Huff GK, et al: Inactivated Propionibacterium acnes (ImmunoRegulin®) as adjunct conventional therapy in the treatment of equine respiratory diseases. Equine Pract 10(6):17-21, 1988.
4. Vail CD, Nestved AJ, Rollins JB, et al: Adjunct treatment of equine respiratory disease complex (ERDC) with Propionibacterium acnes, immunostimulant, EqStim®. Equine Vet Sci 10(6):399-402, 1990.
5. Hamm D, Willeford KO, White G, et al: Caprine serum fraction immunomodulator as a supplemental treatment of lower respiratory disease in the horse. Equine Vet J 34(1):71-75, 2002.
6. Flaminio MJBF, Rush BR, Shuman W: Immunologic function in horses after non-specific immunostimulant administration. Vet Immunol Immunopathol 63(4):303-315, 1998.
7. Andersson M, Gunne H, Agerberth B, et al: NK-lysin, a novel effector peptide of cytotoxic T and NK cells. Structure and cDNA cloning of the porcine form, induction by interleukin 2, and antibacterial and antitumor activity. EMBO J 14(8):1615-1625, 1995.
8. Giguere S, Prescott JF: Quantitation of equine cytokine mRNA expression by reverse transcription-competitive polymerase chain reaction. Vet Immunol Immunopathol 67(1):1-15, 1999.
9. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Ann Biochem 162(1):156-159, 1987.
10. Piatak M, Ka-Cheung L, Williams B, Lifson JD: Quantitative competitive polymerase chain reaction for accurate quantitation of HIV DNA and RNA species. Biotechniques 14(1):70-80, 1993.
11. Cheevers WB, Beyer JC, Knowles DP: Type 1 and Type 2 cytokine gene expression by viral gp135 surface protein-activated T lymphocytes in caprine arthritis-encephalitis lentivirus infection. J Virol 71(8):6259-6263, 1997.
12. Boyadjieva NI, Dokur M, Advis JP, et al: Beta-endorphin modulation of lymphocyte proliferation: Effects of ethanol. Alcohol Clin Exp Res 26(11):1719-1727, 2002.
13. Kansas State University College of Veterinary Medicine: Unpublished data, Dean's Fund DF/99-6, Manhattan, KS, 1999.
14. Chu RS, Askew D, Harding CV: CpG DNA switches on Th1 immunity and modulates antigen-presenting cell function. Curr Topics Microbiol Immunol 274:199-210, 2000.
15. Klinman DM, Yi A-K, Beaucage SL, et al: CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Immuology 93(7):2879-2883, 1996.
16. Kreig AR, Wagner H: Causing a commotion in the blood: Immunotherapy progresses from bacteria to bacterial DNA. Immunol Today 21(10):521-526, 2000.
17. Beignon A-S, Briand J-P, Muller S, Partidos CD: Immunization onto bare skin with synthetic peptides: Immunomodulation with CpG-containing oligonucleotide and effective priming of influenza virus-specific CD4+ T cells. Immunology 105(2):204-212, 2002.
18. Redford TW, Yi A-K, Ward CT, Kreig AM: Cyclosporine A enhances IL-12 production by CpG motifs in bacterial DNA and synthetic oligonucleotides. J Immunol 161(8):3930-3935, 1998.